The aims of this longitudinal model-based meta-analysis (MBMA) were to indirectly compare the time courses of survival probabilities and to identify corresponding potential significant covariates across approved drugs in patients with castration-resistant prostate cancer (CRPC).
A systematic literature review for monotherapy studies in patients with CRPC was conducted up to August 8, 2018. The time courses of progression-free survival (PFS) and overall survival (OS) were fitted with parametric survival models. Covariate analyses were performed to determine the impact of treatment drugs, dosing regimens, and patient characteristics on the survival probabilities. Simulations were carried out to quantify the magnitude of covariate effects.
A total of 146 studies including clinical trials and real-world data on longitudinal survival probabilities in 20,712 patients with CRPC were included in our meta-database. The time courses of PFS and OS probabilities were best described by the log-logistic model. There was no significant difference in median OS and PFS between docetaxel, cabazitaxel, abiraterone acetate, and enzalutamide. There was no significant dose-response relationship in PFS or OS for docetaxel at 50 to 120 mg/m2 every 3 weeks (Q3W) and cabazitaxel at 20 to 25 mg/m2 Q3W. Model-based simulations indicated that PFS probability was associated with chemotherapy, Gleason score, and baseline prostate-specific antigen (BLPSA), while OS probability was associated with chemotherapy, Gleason score, visceral metastasis, Eastern Cooperative Oncology Group performance status, and BLPSA.
Our modeling and simulation framework can be applied to support indirect comparison, dose selection, and go/no-go decision-making for new agents targeting CRPC.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132
D’Amico AV (2014) US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol Off J Am Soc Clin Oncol 32(4):362–364
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS (2013) Castration-resistant prostate cancer: AUA Guideline. J Urol 190(2):429–438
Cookson MS, Lowrance WT, Murad MH, Kibel AS (2015) Castration-resistant prostate cancer: AUA guideline amendment. J Urol 193(2):491–499
Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS (2016) Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol 195(5):1444–1452
Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS (2018) Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol 200(6):1264–1272
U.S. Food and Drug Administration Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. 2018. http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf
Scher HI, Warren M, Heller G (2007) The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 13(5):1488–1492
Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ (2009) Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(17):2766–2771
Gomella LG, Oliver Sartor A (2014) The current role and limitations of surrogate endpoints in advanced prostate cancer. Urol Oncol 32(1):28.e21–28.e29
Armstrong AJ, Febbo PG (2009) Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 14(8):816–827
Chen W, Li L, Ji S, Song X, Lu W, Zhou T (2019) Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis. Eur J Clin Pharmacol 75(11):1521–1532
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol Off J Am Soc Clin Oncol 26(7):1148–1159
Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I (2019) Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther 105(4):899–911
Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, Visser SAG (2019) Model-informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol 8(2):87–96
Ait-Oudhia S, Straubinger RM, Mager DE (2012) Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res 29(10):2833–2844
Ocampo-Pelland AS, Gastonguay MR, French JF, Riggs MM (2016) Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data. J Pharmacokinet Pharmacodyn 43(2):191–206
Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2010) Disease progression meta-analysis model in Alzheimer’s disease. Alzheimers Dement 6(1):39–53
William-Faltaos D, Chen Y, Wang Y, Gobburu J, Zhu H (2013) Quantification of disease progression and dropout for Alzheimer’s disease. Int J Clin Pharmacol Ther 51(2):120–131
Wang X, Shang D, Ribbing J, Ren Y, Deng C, Zhou T, Guo F, Lu W (2012) Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second. Eur J Clin Pharmacol 68(8):1157–1166
Mandema JW, Boyd RA, DiCarlo LA (2011) Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis. Clin Pharmacol Ther 90(6):820–827
Gibbs JP, Fredrickson J, Barbee T et al (2012) Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol 52(10):1494–1505
Ren YP, Xie RJ, Marshall S, Li L, Zhou TY, Lu W (2015) Model-based meta-analysis of the effects of non-selective and alpha1-selective GABAA receptor agonists in healthy volunteers. Eur J Clin Pharmacol 71(10):1209–1221
Dodds MG, Salinger DH, Mandema J, Gibbs JP, Gibbs MA (2013) Clinical trial simulation to inform phase 2: comparison of concentrated vs. distributed first-in-patient study designs in psoriasis. CPT Pharmacometrics Syst Pharmacol 2:e58
Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D (2005) Model-based development of gemcabene, a new lipid-altering agent. AAPS J 7(3):E513–E522
Halabi S, Kelly WK, Zhou H et al (2014) The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): a meta-analysis of five phase III trials. J Clin Oncol 32:5s
Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB, Generali D (2016) Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer 61:111–121
Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA (2017) Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget 8(48):84572–84578
Iacovelli R, Altavilla A, Procopio G, Bracarda S, Santoni M, Cascinu S, Cortesi E (2013) Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. Prostate Cancer Prostatic Dis 16(4):323–327
Ahn JE, French JL (2010) Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37(2):179–201
Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Prog Biomed 75(2):85–94
Mandema JW, Gibbs M, Boyd RA, Wada DR, Pfister M (2011) Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin Pharmacol Ther 90(6):766–769
Mahmud S, Franco E, Aprikian A (2004) Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90(1):93–99
King CR (2016) The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol 121(2):199–203
Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85(3):686–692
Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB (2015) What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 115(3):295–300
Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, de Placido S, di Lorenzo G (2013) Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol 9(6):889–897
Tomioka A, Tanaka N, Yoshikawa M et al (2014) Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol 14:33
Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES (2017) Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol 9(8):565–573
Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 32(7):671–677
Mottet N, Clarke N, De Santis M, Zattoni F, Morote J, Joniau S (2015) Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? BJU Int 115(3):364–372
Oosterlinck W, Mattelaer J, Derde MP, Kaufman L (1995) Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients. Acta Urol Belg 63(3):1–9
Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D, de Giorgi U (2014) Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer 21(3):487–493
Liao SG, Cheng HH, Lei Y (2016) C-Reactive protein is a prognostic marker for patients with castration-resistant prostate cancer. Oncol Res Treat 39(5):266–271
Oudard S, Fizazi K, Sengelov L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol Off J Am Soc Clin Oncol 35(28):3189–3197
Tan PS, Haaland B, Montero AJ, Kyriakopoulos CE, Lopes G (2014) Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison. Clin Med Insights Oncol 8:29–36
Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R (2018) Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol 73(6):834–844
Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES (2014) The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 66(4):646–652
Miyake H, Hara T, Ozono S, Fujisawa M (2017) Impact of prior use of an androgen receptor-Axis-targeted (ARAT) agent with or without subsequent taxane therapy on the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 15(2):e217–e222
Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV (2014) Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65(1):30–36
Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY (2015) Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis 18(2):122–127
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154
Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate Cancer-PROSELICA. J Clin Oncol Off J Am Soc Clin Oncol 35(28):3198–3206
Oyinlola JO, Campbell J, Kousoulis AA (2016) Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res 16:299
Bate A, Juniper J, Lawton AM, Thwaites RM (2016) Designing and incorporating a real world data approach to international drug development and use: what the UK offers. Drug Discov Today 21(3):400–405
Liu Q, Ramamoorthy A, Huang SM (2019) Real-world data and clinical pharmacology: a regulatory science perspective. Clin Pharmacol Ther 106(1):67–71
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016) Real-world evidence - what is it and what can it tell us? N Engl J Med 375(23):2293–2297
Conflict of interest
The authors declare that they have no conflict of interest.
The views expressed in this paper are those of the authors and do not necessarily represent those of the China National Medical Products Administration.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Chen, W., Li, L., Ji, S. et al. Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer. Eur J Clin Pharmacol (2020) doi:10.1007/s00228-020-02829-9
- Model-based meta-analysis
- Castration-resistant prostate cancer
- Progression-free survival
- Overall survival
- Longitudinal data